NASDAQ · Drug Manufacturers - Specialty & Generic

Regencell Bioscience Holdings Limited (RGC) Stock

$7.35 -3.67% NASDAQ: RGC Healthcare

Valuation

MetricValue
Price$7.35
Market Cap$3.64B
P/E Ratio-437.76
P/B Ratio2520.82
P/S Ratio0.00
EPS (TTM)$-0.01
52-Week High$69.00
52-Week Low$4.51
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-231.87%
ROA-233.91%
ROCE-529.30%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.32
Current Ratio5.00

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-1.0M$-8.0M$-6.0M$-5.0M$-4.0M
Net Profit$-1.0M$-7.0M$-6.0M$-4.0M$-4.0M
EPS$0.00$-0.01$-0.01$-0.01$-0.01
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$0$18.0M$13.0M$8.0M$6.0M
Total Liabilities$4.0M$1.0M$1.0M$0$1.0M
Cash$0$6.0M$2.0M$3.0M$2.0M
Borrowings$4.0M$1.0M$0$0$1.0M

Latest News

Auditor Change Puts Regencell Bioscience Governance And Cash Runway In Focus Simply Wall St. · Apr 27, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-1.0M$-5.0M$-5.0M$-4.0M$-3.0M
Investing Cash Flow$0$-12.0M$0$5.0M$3.0M
Financing Cash Flow$0$22.0M$0$0$0
Net Cash Flow$0$6.0M$-5.0M$1.0M$-1.0M
Free Cash Flow$-1.0M$-6.0M$-5.0M$-4.0M$-3.0M

Valuation & Return Ratios

MetricValue
PEG Ratio4.52
EV / EBITDA-437.82
FCF Yield-0.08%
Quick Ratio1.42
Interest Coverage0.00
Return 1Y-56.51%
Return 3Y1029.55%
Return 5Y2368.97%

Ownership

Insiders Held88.38%
Institutions Held0.14%
Institutions Float Held1.16%
Institutional HolderSharesReport Date
Geode Capital Management, LLC415,5692026-03-31
GSA Capital Partners LLP31,5692026-03-31
Marex Group Plc31,6002026-03-31
Vident Advisory, LLC 29,5882026-03-31
Squarepoint Ops LLC26,6132026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AMLXAmylyx Pharmaceuticals, Inc. $28.14 +3.46% -19.71 $3.13B 0.00%
AXSMAxsome Therapeutics, Inc. $168.35 -1.02% -49.17 $8.66B 0.00%
HRMYHarmony Biosciences Holdings, Inc. $40.28 +1.72% 12.66 $2.33B 0.00%
LBRXLB Pharmaceuticals Inc $37.22 +7.54% -12.45 $1.07B 0.00%
PRAXPraxis Precision Medicines, Inc. $259.86 -1.40% -22.82 $7.24B 0.00%

About Regencell Bioscience Holdings Limited

Regencell Bioscience Holdings Limited (RGC) stock trades at $7.35 with a market capitalization of $3.64B. The stock is valued at a price-to-earnings (P/E) ratio of -437.76, price-to-book of 2520.82, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $4.51 and $69.00, and currently trades 89.3% below its 52-week high.

On profitability, Regencell Bioscience Holdings Limited generates a return on equity (ROE) of -231.87%, return on capital employed of -529.30%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides